Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized), End User (Hospital, Diagnostic Lab, Research)—Global Forecast to 2030

Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized), End User (Hospital, Diagnostic Lab, Research)—Global Forecast to 2030


The autoimmune disease diagnostics market is expected to reach $9.84 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the autoimmune disease diagnostics market is attributed to the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases. However, difficulties in diagnosing autoimmune diseases restrain the growth of this market. Emerging economies and increasing investments & funding in the autoimmune diseases space are expected to generate growth opportunities for the players in this market. Moreover, the unfavorable reimbursement scenario and high rate of delayed diagnosis or misdiagnosis are major challenges for market growth.

Based on product type, the autoimmune disease diagnostics market is segmented into reagents, assays & kits, and instruments. The reagents, assays & kits segment is expected to grow at the fastest CAGR during the forecast period. The growing prevalence of autoimmune diseases, recurrent use of reagents, assays & kits, and their increasing number of launches for autoimmune diseases by major market players are the major factors responsible for the segment growth.

The growing prevalence of autoimmune diseases has prompted major players operating in the autoimmune disease diagnostics market to focus on developing, approving, and launching kits & assays for monitoring and diagnosing autoimmune diseases, further driving their adoption. For instance, in 2022, Thermo Fisher Scientific Inc. (U.S.) launched EliA RNA Pol III and EliA Rib-P blood tests for the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE). This test further expands the company's product offerings for autoimmune disease diagnostics.

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibodies test (ANA), C-reactive protein test (CRP), erythrocyte sedimentation rate test, rheumatoid factor test, immunoglobulins test, routine blood tests, and other test types. In 2023, the antinuclear antibodies test (ANA) segment is expected to account for the largest share of the market. This segment's large market share is attributed to the increasing prevalence of autoimmune diseases and the widespread use of the ANA test for diagnosing autoimmune diseases due to its affordability, ease of administration, and heightened sensitivity & specificity.

According to the National Stem Cells Foundation, over 80 autoimmune diseases affect nearly 4% of the global population. The high burden of autoimmune diseases leads to the adoption of the antinuclear antibodies test, which is used as a primary test for several autoimmune diseases.

Based on disease type, the autoimmune disease diagnostics market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. In 2023, the systemic autoimmune diseases segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the higher prevalence of systemic autoimmune diseases compared to organ-specific conditions, increasing initiatives to raise awareness about these diseases, and the continuous growth in research activities related to autoimmune conditions. The Arthritis Foundation (AF) estimates that the global prevalence of RA is 0.5 to 1% in developed countries. A 2020 review found that the prevalence of RA in the Middle East and Africa ranged from 0.06 to 3.4%. Rheumatoid arthritis requires long-term monitoring and management.

Based on end user, the autoimmune disease diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, and academic & research institutes. In 2023, the diagnostic laboratories segment is expected to account for the largest share of the market. Diagnostic laboratories receive samples from various healthcare centers, including hospitals and clinics. Diagnostics laboratories are crucial in providing accurate diagnostic results and managing disease management. Diagnostic laboratories process more samples in less time due to the well-equipped systems and the presence of skilled professionals. These factors contribute to the large market share of this segment in the autoimmune diseases diagnostics market.

An in-depth analysis of the geographical scenario of the autoimmune disease diagnostics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. The market growth in this region is attributed to the growing prevalence and incidence of celiac diseases & rheumatoid arthritis, unhealthy lifestyle, government initiatives supporting research in autoimmune diseases, and increasing expenditure on the research of autoimmune diseases.

Some of the key players operating in the global autoimmune disease diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).

Scope of the Report

Autoimmune Disease Diagnostics Market, by Product Type


Reagents, Assays, and Kits
Instruments
Software & Services

Autoimmune Disease Diagnostics Market, by Test Type

Antinuclear Antibodies (ANA) Test
Rheumatoid Factor Test
Immunoglobulins Test
Routine Blood Tests Test
C-reactive Protein (CRP) Test
Erythrocyte Sedimentation Rate (ESR) Test
Other Test Types

(Note – Other test types include (Anti-double stranded DNA, Extractable nuclear antigen, Anti-signal recognition particle tests, Ferritin, and Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibodies)

Autoimmune Disease Diagnostics Market, by Disease Type

Systemic Autoimmune Diseases
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematosus
Multiple Sclerosis
Other Systemic Autoimmune Diseases(Other systemic autoimmune diseases include systemic scleroderma, dermatomyositis, Sjögren's syndrome, mixed connective tissue disease, Behçet syndrome, sarcoidosis, and myasthenia gravies, among others)
Organ-specific Autoimmune Diseases
Type-1 Diabetes
Celiac Diseases
Inflammatory Bowel Disease
Other Organ-Specific Diseases(Other organ-specific autoimmune diseases include Addison’s disease, Grave’s disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, and Sclerosing cholangitis, among others)

Autoimmune Disease Diagnostics Market, by End User

Hospitals & Clinics
Diagnostic Laboratories
Academic & Research Institutes

Autoimmune Disease Diagnostics Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Autoimmune Disease Diagnostics Market - Report Summary
Report MetricsDetails
Years Considered2021 - 2030
Base Year2022
Forecast Period2023-2030
Page Count261
Units ReferencedValue (USD Million)
Segments/Key TopicsMarket by Product Type, Test Type, Disease Type, and End User
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies MentionedThermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).


FAQs About the Report

What is the scope of the autoimmune disease diagnostics market study?


The autoimmune disease diagnostics market report covers the market sizes & forecasts based on product, test type, disease type, end user, and geography. This report involves the value analysis of various segments and subsegments of the autoimmune disease diagnostics market at the regional and country levels.

What is the revenue generated from autoimmune disease diagnostics across the globe? At what rate is their demand expected to grow for the next 5–7 years?

The autoimmune disease diagnostics market is projected to reach $9.84 billion by 2030, at a CAGR of 7.2% during the forecast period of 2023–2030.

What are the various products in the autoimmune disease diagnostics market, and which product holds the major share?

Based on the product, the autoimmune disease diagnostics market is segmented into reagents, assays, kits, instruments, and software & services. In 2023, the reagents, assays, and kits segment is expected to account for the largest share of the autoimmune disease diagnostics market due to the large market share of this segment is attributed to the frequent use of kits, assays, and reagents during the diagnosis of a wide range of autoimmune diseases. Furthermore, the growing prevalence of autoimmune diseases, especially among the geriatric population, and the increasing launches of kits and assays for autoimmune diseases by major market players contribute to the segment's growth.

What are the various test types in the autoimmune disease diagnostics market, and which test type holds the major share?

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibodies (ANA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins, routine blood tests, and other test types. In 2023, the antinuclear antibody (ANA) segment is expected to account for the largest share of the autoimmune disease diagnostics market due to the increasing prevalence of autoimmune diseases and the widespread use of the ANA test for diagnosing autoimmune diseases due to its affordability, ease of administration, and heightened sensitivity & specificity.

What are the types of diseases in the autoimmune disease diagnostics market, and which disease type holds the major share?

Based on disease type, the autoimmune disease diagnostics market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. In 2023, the systemic autoimmune diseases segment is expected to account for the largest share of the autoimmune disease diagnostics market.

What end users are involved in the autoimmune disease diagnostics market, and which end user holds the major share?

Based on end user, the autoimmune disease diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, and academic & research institutes. In 2023, the hospitals & clinics segment is estimated to account for the largest share of the Autoimmune Disease Diagnostics market.

What are the key factors supporting the growth of this market? What are the major opportunities for the market players in the autoimmune disease diagnostics market?

The growth of the autoimmune disease diagnostics market is driven by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases. Moreover, emerging economies and increasing investments & funding in the autoimmune diseases space are expected to generate growth opportunities for the players in this market.

Who are the major players operating in the autoimmune disease diagnostics market?

The key players operating in the Autoimmune Disease Diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the Autoimmune Disease Diagnostics market?

The Asia-Pacific region is slated to witness the highest growth rate during the forecast period and offers significant growth opportunities for the players in this market. The fast market growth in Asia-Pacific is attributed to factors such as the growing prevalence and incidence of celiac diseases & rheumatoid arthritis, unhealthy lifestyle, government initiatives regarding autoimmune diseases, and increasing expenditure on the research of autoimmune diseases.


1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process Of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of The Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Increasing Prevalence of Autoimmune Disorders Driving Growth in Diagnostic Testing
4.2.1.2. Rising Awareness Regarding Autoimmune Diseases Boosting the Adoption of Diagnostic Products
4.2.1.3. Increasing Investments & Funding in The Autoimmune Diseases Space Generating Market Growth Opportunities
4.2.2. Factor Analysis
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Buyers
4.3.2. Bargaining Power of Suppliers
4.3.3. Threat of Substitutes
4.3.4. Threat of New Entrants
4.3.5. Degree of Competition
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Europe
4.4.3. Asia-Pacific
4.4.3.1. China
4.4.3.2. India
4.4.3.3. Japan
4.4.4. Latin America
4.4.5. Middle East & Africa
5. Autoimmune Disease Diagnostics Market Assessment— by Product Type
5.1. Overview
5.2. Reagents, Kits, & Assays
5.3. Instruments
5.4. Software & Services
6. Autoimmune Disease Diagnostics Market Assessment—by Test Type
6.1. Overview
6.2. Antinuclear Antibodies (ANA) Test
6.3. C-Reactive Protein Test
6.4. Erythrocyte Sedimentation Rate Test
6.5. Rheumatoid Factor Test
6.6. Immunoglobulins Test
6.7. Routine Blood Test
6.8. Other Autoimmune Tests
7. Global Autoimmune Disease Diagnostics Market—by Disease Type
7.1. Overview
7.2. Systemic Autoimmune Diseases
7.2.1. Rheumatoid Arthritis
7.2.2. Psoriasis
7.2.3. Systemic Lupus Erythematosus
7.2.4. Multiple Sclerosis
7.2.5. Other Systemic Autoimmune Diseases
7.3. Organ-specific Autoimmune Diseases
7.3.1. Type-1 Diabetes
7.3.2. Celiac Disease
7.3.3. Inflammatory Bowel Diseases
7.3.4. Other Organ-specific Autoimmune Diseases
8. Autoimmune Disease Diagnostics Market Assessment—by End User
8.1. Overview
8.2. Diagnostic Laboratories
8.3. Hospitals & Clinics
8.4. Academic & Research Institutes
9. Autoimmune Disease Diagnostics Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. Italy
9.3.4. Spain
9.3.5. France
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1 Abbott Laboratories
11.2. F. Hoffmann-La Roche Ltd.
11.3. Siemens Healthineers AG (A Subsidiary of Siemens AG)
11.4. Thermo Fisher Scientific, Inc.
11.5. Bio-Rad Laboratories, Inc.
11.6. Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
11.7. Becton, Dickinson and Company
11.8. PerkinElmer, Inc.
11.9. Grifols, S.A.
11.10. Creative Diagnostics
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Autoimmune Disease Diagnostics Market, By Product Type, 2021-2030 (USD Million)
Table 2 Global Autoimmune Disease Diagnostics Market for Reagents, Kits, And Assays, By Country/Region, 2021–2030 (USD Million)
Table 3 Global Autoimmune Disease Diagnostics Market for Instruments, By Country/Region, 2021–2030 (USD Million)
Table 4 Global Autoimmune Disease Diagnostics Market for Software & Services, By Country/Region, 2021–2030 (USD Million)
Table 5 Global Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 6 Global Antinuclear Antibodies (ANA) Test Market, By Country/Region, 2021–2030 (USD Million)
Table 7 Global C-Reactive Protein Test Market, By Country/Region, 2021–2030 (USD Million)
Table 8 Global Erythrocyte Sedimentation Rate Test Market, By Country/Region, 2021–2030 (USD Million)
Table 9 Global Rheumatoid Factor Test Market, By Country/Region, 2021–2030 (USD Million)
Table 10 Global Immunoglobulin Test Market, By Country/Region, 2021–2030 (USD Million)
Table 11 Global Routine Blood Test Market, By Country/Region, 2021–2030 (USD Million)
Table 12 Global Other Autoimmune Test Market, By Country/Region, 2021–2030 (USD Million)
Table 13 Global Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 14 Global Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 15 Global Systemic Autoimmune Disease Diagnostics Market by Country/Region, 2021–2030 (USD Million)
Table 16 Global Rheumatoid Arthritis Diagnostics Market by Country/Region, 2021–2030 (USD Million)
Table 17 Global Psoriasis Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 18 Global Systemic Lupus Erythematosus Diagnostics Market by Country/Region, 2021–2030 (USD Million)
Table 19 Global Multiple Sclerosis Diagnostics Market by Country/Region, 2021–2030 (USD Million)
Table 20 Global Other Systemic Autoimmune Diseases Diagnostics Market by Country/Region, 2021–2030 (USD Million)
Table 21 Global Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 22 Global Organ-specific Autoimmune Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 23 Global Type-1 Diabetes Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 24 Global Celiac Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 25 Research Studies for Crohn's Disease and Ulcerative Colitis in Canada
Table 26 Global Inflammatory Bowel Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 27 Global Other Organ-specific Autoimmune Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 28 Global Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 29 Global Autoimmune Disease Diagnostics Market for Diagnostic Laboratories, By Country/Region, 2021–2030 (USD Million)
Table 30 Global Autoimmune Disease Diagnostics Market for Hospitals & Clinics, By Country/Region, 2021–2030 (USD Million)
Table 31 Global Autoimmune Disease Diagnostics Market for Academic & Research Institutes, By Country/Region, 2021–2030 (USD Million)
Table 32 Global Autoimmune Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 33 North America: Autoimmune Disease Diagnostics Market, By Country, 2021–2030 (USD Million)
Table 34 North America.: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 35 North America.: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 36 North America.: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 37 North America: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 38 North America: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 39 North America: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 40 U.S.: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 41 U.S.: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 42 U.S.: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 43 U.S.: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 44 U.S.: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 45 U.S.: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 46 Canada: Arthritis Prevalence, 2018—2021
Table 47 Canada: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 48 Canada: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 49 Canada: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 50 Canada: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 51 Canada: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 52 Canada: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 53 Europe: Autoimmune Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 54 Europe: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 55 Europe: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 56 Europe: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 57 Europe: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 58 Europe: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 59 Europe: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 60 Germany: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 61 Germany: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 62 Germany: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 63 Germany: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 64 Germany: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 65 Germany: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 66 U.K.: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 67 U.K.: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 68 U.K.: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 69 U.K.: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 70 U.K.: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 71 U.K.: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 72 Italy: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 73 Italy: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 74 Italy: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 75 Italy: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 76 Italy: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 77 Italy: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 78 Spain: Number of People with Type 1 Diabetes (2022)
Table 79 Spain: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 80 Spain: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 81 Spain: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 82 Spain: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 83 Spain: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 84 Spain: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 85 France: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 86 France: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 87 France: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 88 France: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 89 France: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 90 France: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 91 Rest of Europe: Number of People with Type 1 Diabetes, 2022
Table 92 RoE: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 93 RoE: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 94 RoE: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 95 RoE: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 96 RoE: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 97 RoE: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 98 Asia-Pacific: Autoimmune Disease Diagnostics Market, By Country/Region, 2021–2030 (USD Million)
Table 99 Asia-Pacific: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 100 Asia-Pacific: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 101 Asia-Pacific: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 102 Asia-Pacific: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 103 Asia-Pacific: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 104 Asia-Pacific: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 105 China: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 106 China: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 107 China: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 108 China: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 109 China: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 110 China: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 111 Comparison of Type 1 Diabetes in Asia-Pacific Countries (2022)
Table 112 India: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 113 India: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 114 India: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 115 India: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 116 India: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 117 India: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 118 Japan: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 119 Japan: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 120 Japan: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 121 Japan: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 122 Japan: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 123 Japan: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 124 RoAPAC: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 125 RoAPAC: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 126 RoAPAC: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 127 RoAPAC: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 128 RoAPAC: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 129 RoAPAC: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 130 Latin America: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 131 Latin America: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 132 Latin America: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 133 Latin America: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 134 Latin America: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 135 Latin America: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 136 Middle East & Africa: Autoimmune Disease Diagnostics Market, By Product Type, 2021–2030 (USD Million)
Table 137 Middle East & Africa: Autoimmune Disease Diagnostics Market, By Test Type, 2021–2030 (USD Million)
Table 138 Middle East & Africa: Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 139 Middle East & Africa: Systemic Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 140 Middle East & Africa: Organ-specific Autoimmune Disease Diagnostics Market, By Disease Type, 2021–2030 (USD Million)
Table 141 Middle East & Africa: Autoimmune Disease Diagnostics Market, By End User, 2021–2030 (USD Million)
Table 142 Recent Developments, By Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Autoimmune Disease Diagnostics Market Size, By Product Type, 2023 Vs. 2030 (USD Million)
Figure 8 Global Autoimmune Disease Diagnostics Market Size, By Test Type, 2023 Vs. 2030 (USD Million)
Figure 9 Global Autoimmune Disease Diagnostics Market Size, By Disease Type, 2023 Vs. 2030 (USD Million)
Figure 10 Global Autoimmune Disease Diagnostics Market Size, By End User, 2023 Vs. 2030 (USD Million)
Figure 11 Autoimmune Disease Diagnostics Market Size, By Geography
Figure 12 Impact Analysis of Market Dynamics
Figure 13 National Institutes of Health: Research Funding for Autoimmune Diseases, 2021–2024 (USD Million)
Figure 14 Number of People with Type-1 Diabetes, By Country, 2022
Figure 15 Global Prevalence of Multiple Sclerosis Per 100,000 People, 2013 Vs. 2020
Figure 16 U.S.: Research Funding for Multiple Sclerosis, 2018-2024 (USD Million)
Figure 17 Porter’s Five Forces Analysis
Figure 18 EU Regulatory Pathway - IVDR 2017/746
Figure 19 China: Medical Device Registration Flow Chart (SFDA)
Figure 20 Saudi Arabia: Regulatory Landscape/Marketing Approval Process
Figure 21 Global Autoimmune Disease Diagnostics Market, By Product Type, 2023 Vs. 2030 (USD Million)
Figure 22 Global Autoimmune Disease Diagnostics Market, By Test Type, 2023 Vs. 2030 (USD Million)
Figure 23 U.S.: Number of People with Arthritis (Million) (2020-2035)
Figure 24 Global Ageing Population, By Region (2019 Vs. 2030)
Figure 25 Global Autoimmune Disease Diagnostics Market, By Disease Type, 2023 Vs. 2030 (USD Million)
Figure 26 Multiple Sclerosis Global Prevalence Per 100,000 People (2013 Vs. 2020)
Figure 27 Research Funding for Multiple Sclerosis in The U.S., 2018-2024 (USD Million)
Figure 28 Number of People with Type-1 Diabetes (2022)
Figure 29 Research Funding to NIH For Myasthenia Gravis (2018-2024)
Figure 30 Global Autoimmune Disease Diagnostics Market, By End User, 2023 Vs. 2030 (USD Million)
Figure 31 Global Autoimmune Disease Diagnostics Market, By Region, 2023 Vs. 2030 (USD Million)
Figure 32 North America: Autoimmune Disease Diagnostics Market Snapshot
Figure 33 Europe: Autoimmune Disease Diagnostics Market Snapshot
Figure 34 Germany: Deaths Due to Musculoskeletal and Connective Tissue Diseases, 2015-2020
Figure 35 U.K.: Number of Cases Type 1 Diabetes (0-19 Years), 2019—2022
Figure 36 Italy: Gpd Percentage Spent on Healthcare, 2015—2021
Figure 37 Spain: Number of People Living with HIV (2010-2021)
Figure 38 Asia-Pacific: Autoimmune Disease Diagnostics Market Snapshot
Figure 39 China: Wheat Consumption (1000 Mt) 2015-2022
Figure 40 Japan: Percentage of Population Aged 65 Years and Above (2010-2030)
Figure 41 Australia: Government Research Expenditure on Immunological Diseases 2017 Vs 2020 (USD Million)
Figure 42 Colombia: Lupus Cases 2016-2021
Figure 43 Middle East & North Africa: Healthcare Expenditure (% Of GDP) (2014-2020)
Figure 44 Key Growth Strategies Adopted by Leading Players 2020-2023
Figure 45 Autoimmune Disease Diagnostics Market: Competitive Benchmarking by Test Type
Figure 46 Autoimmune Disease Diagnostics Market: Competitive Benchmarking, By Region
Figure 47 Competitive Dashboard: Autoimmune Disease Diagnostics Market
Figure 48 Abbott Laboratories: Financial Overview (2022)
Figure 49 F. Hoffman-La Roche Ltd: Financial Overview (2021)
Figure 50 Siemens Healthineers AG (A Subsidiary of Siemens AG): Financial Overview (2022)
Figure 51 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 52 Bio-Rad Laboratories: Financial Overview (2022)
Figure 53 Danaher Corporation: Financial Overview (2022)
Figure 54 Becton, Dickinson and Company: Financial Overview (2022)
Figure 55 PerkinElmer, Inc.: Financial Overview (2022)
Figure 56 Grifols, S.A.: Financial Overview (2022)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings